No Notes Added Yet
Business
Oceanaa Biotek Industries Ltd. is an Indian company primarily engaged in the aquaculture sector. Its core business model revolves around integrated shrimp farming, encompassing hatchery operations, shrimp feed production, and the cultivation of various shrimp species. The company also processes shrimp and develops value-added seafood products. It makes money by selling farmed shrimp and shrimp-related products to domestic and international markets.
Revenue Mix
The company's primary revenue streams are derived from its aquaculture operations, particularly the farming and processing of shrimp. While specific revenue contributions by segment are not consistently detailed publicly, its activities span:
Shrimp Hatchery (producing shrimp seeds/post-larvae)
Shrimp Farming (cultivation of Vannamei and other species)
Shrimp Feed Manufacturing
Processing and Export of Farmed Shrimp
Industry
The Indian aquaculture industry is a significant global player, particularly in shrimp production and export, benefiting from extensive coastline and suitable climate. It is characterized by a mix of large integrated players and numerous smaller farmers. Oceanaa Biotek Industries Ltd. operates as an integrated player within this industry, aiming for efficiency across its value chain from hatchery to processing. Its positioning likely emphasizes quality, biosecurity, and potentially sustainable practices to cater to both domestic and international demand, competing with other established shrimp exporters in India.
MOAT
Oceanaa Biotek's competitive advantages, if any, likely stem from:
Integrated Operations: Control over the entire value chain from hatchery to feed and processing can lead to cost efficiencies, quality control, and reduced reliance on external suppliers.
Biosecurity & Disease Management: Expertise in preventing and managing common aquaculture diseases, which are a major risk in the industry.
Scale and Technology: Investment in modern farming techniques and processing infrastructure can improve yields and product quality.
Market Access: Established relationships with domestic and international buyers for its seafood products.
Growth Drivers
Key factors that can drive growth for Oceanaa Biotek over the next 3-5 years include:
Rising Global Seafood Consumption: Increasing demand for protein-rich, healthy food sources, particularly shrimp.
Expanding Export Markets: India's competitive position in the global shrimp market continues to drive export opportunities.
Technological Advancements: Adoption of advanced farming techniques (e.g., biofloc, recirculation aquaculture systems) to improve yields and sustainability.
Value-Added Products: Focus on processing and producing higher-margin value-added shrimp products.
Government Support: Favorable policies and subsidies for aquaculture development in India.
Risks
Key business risks include:
Disease Outbreaks: Vulnerability to diseases like White Spot Syndrome (WSSV) in shrimp, which can devastate harvests.
Environmental & Climate Risks: Impact of extreme weather events, water quality degradation, and climate change on farming operations.
Feed Price Volatility: Fluctuations in raw material prices for shrimp feed can impact profitability.
Regulatory Changes: Evolving environmental norms, export policies, and food safety standards can impose compliance costs.
Market Price Fluctuations: Global shrimp prices are subject to supply-demand dynamics, impacting revenue and margins.
Competition: Intense competition from other domestic and international shrimp producers.
Management & Ownership
Oceanaa Biotek Industries Ltd. is promoted by individuals with experience in the aquaculture sector. Typically, Indian companies have strong promoter groups who hold significant ownership stakes and often lead the management team. The quality of management would depend on their track record in navigating industry challenges, executing expansion plans, and maintaining financial health. Ownership structure generally involves a substantial promoter holding, with the remainder held by public shareholders.
Outlook
Oceanaa Biotek operates in a dynamic sector with significant growth potential, driven by robust global demand for seafood. Its integrated business model offers some resilience against market fluctuations and potential for efficiency. However, the company faces inherent risks such as disease outbreaks, climate change impacts, and price volatility, which are common to the aquaculture industry. Success will depend on its ability to leverage technological advancements, maintain stringent biosecurity, manage operational costs effectively, and expand its market reach while navigating the inherent environmental and market challenges.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 14 | 8 | 3 | 5 | 5 | 3 | 13 | 5 | 4 | 1 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 14 | 8 | 3 | 5 | 5 | 3 | 13 | 5 | 4 | 1 |
| Total Expenditure | 11 | 7 | 27 | 3 | 3 | 2 | 13 | 3 | 3 | 2 |
| Operating Profit | 3 | 1 | -24 | 2 | 2 | 1 | -0 | 2 | 1 | -1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 2 | 0 | -24 | 1 | 1 | 1 | -1 | 1 | 0 | -1 |
| Provision for Tax | 1 | 0 | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 |
| Profit After Tax | 2 | 0 | -24 | 1 | 1 | 1 | -1 | 1 | 0 | -1 |
| Adjustments | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 2 | 0 | -24 | 1 | 1 | 1 | -1 | 1 | 0 | -1 |
| Adjusted Earnings Per Share | 1.2 | 0.1 | -17.5 | 0.9 | 1 | 0.8 | -1 | 0.9 | 0.1 | -1.1 |
| #(Fig in Cr.) | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 0 | 0 | 7 | 46 | 32 | 36 | 60 | 36 | 26 | 23 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 0 | 0 | 0 | 7 | 46 | 32 | 36 | 61 | 36 | 26 | 23 |
| Total Expenditure | 0 | 0 | 0 | 6 | 44 | 27 | 31 | 39 | 54 | 21 | 21 |
| Operating Profit | -0 | -0 | 0 | 1 | 2 | 5 | 5 | 21 | -18 | 5 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 3 | 2 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -0 | -0 | 0 | 1 | 1 | 4 | 4 | 17 | -21 | 2 | -1 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 6 | -1 | 0 | 0 |
| Profit After Tax | -0 | -0 | 0 | 0 | 1 | 2 | 3 | 11 | -20 | 2 | -1 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -0 | -0 | 0 | 0 | 1 | 2 | 3 | 11 | -20 | 2 | -1 |
| Adjusted Earnings Per Share | -12.4 | -8.4 | 0.1 | 0.4 | 0.8 | 2.1 | 2.7 | 8.1 | -14.8 | 1.6 | -1.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -28% | -10% | -11% | 0% |
| Operating Profit CAGR | 0% | 0% | 20% | 0% |
| PAT CAGR | 0% | -13% | 15% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 0% | -32% | -19% | -18% |
| ROE Average | 8% | -4% | 6% | 5% |
| ROCE Average | 10% | 4% | 15% | 11% |
| #(Fig in Cr.) | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | -0 | -0 | 3 | 6 | 10 | 12 | 15 | 45 | 25 | 27 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Other Non-Current Liabilities | 0 | 0 | 0 | -0 | 0 | -0 | 0 | 1 | 0 | 0 |
| Total Current Liabilities | 0 | 0 | 0 | 4 | 3 | 7 | 7 | 13 | 13 | 12 |
| Total Liabilities | 0 | 0 | 3 | 10 | 13 | 19 | 22 | 60 | 39 | 41 |
| Fixed Assets | 0 | 0 | 0 | 0 | 7 | 7 | 6 | 24 | 17 | 21 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 0 | 0 | 3 | 10 | 6 | 13 | 17 | 36 | 23 | 20 |
| Total Assets | 0 | 0 | 3 | 10 | 13 | 19 | 22 | 60 | 39 | 41 |
| #(Fig in Cr.) | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | 0 | 0 | 0 | -0 | 2 | 1 | 1 | 2 | -5 | 7 |
| Cash Flow from Investing Activities | 0 | 0 | 0 | 0 | -8 | -1 | -0 | -22 | 5 | -6 |
| Cash Flow from Financing Activities | 0 | 0 | 0 | 2 | 4 | -0 | -0 | 20 | -0 | -0 |
| Net Cash Inflow / Outflow | 0 | 0 | 0 | 2 | -2 | 0 | -0 | 0 | -0 | 0 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -12.45 | -8.44 | 0.05 | 0.39 | 0.79 | 2.13 | 2.7 | 8.06 | -14.78 | 1.63 |
| CEPS(Rs) | -12.45 | -8.44 | 0.05 | 0.4 | 1.4 | 3.45 | 3.78 | 10.62 | -12.94 | 3.23 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0.35 | 0.6 | 1.5 | 0 | 0 |
| Book NAV/Share(Rs) | -49.51 | -45.11 | 5.77 | 6.21 | 10.02 | 11.73 | 14.8 | 33.35 | 18.62 | 20.26 |
| Core EBITDA Margin(%) | 0 | -111.59 | 12.19 | 11.16 | 4.54 | 15.98 | 14.7 | 34.77 | -49.33 | 18.45 |
| EBIT Margin(%) | 0 | -111.59 | 12.19 | 8.68 | 2.85 | 11.35 | 11.8 | 29.16 | -56.22 | 10.11 |
| Pre Tax Margin(%) | 0 | -116.66 | 12.18 | 8.59 | 2.73 | 11 | 11.71 | 27.97 | -56.68 | 9.71 |
| PAT Margin (%) | 0 | -143.53 | 8.36 | 5.19 | 1.74 | 6.78 | 7.49 | 18.09 | -55.27 | 8.64 |
| Cash Profit Margin (%) | 0 | -143.53 | 8.36 | 5.3 | 3.08 | 10.95 | 10.5 | 23.82 | -48.37 | 17.07 |
| ROA(%) | -63.4 | -96.04 | 1.71 | 5.35 | 6.98 | 13.28 | 13.19 | 26.44 | -40.26 | 5.53 |
| ROE(%) | 0 | 0 | 1.91 | 8.12 | 10.25 | 19.62 | 20.32 | 36.25 | -56.88 | 8.41 |
| ROCE(%) | 0 | 0 | 2.76 | 13.58 | 16.7 | 32.59 | 31.89 | 57.2 | -56.03 | 9.52 |
| Receivable days | 0 | 0 | 6.16 | 114.98 | 36.54 | 43.33 | 36.82 | 47.33 | 107.81 | 112.91 |
| Inventory Days | 0 | 0 | 184.11 | 0 | 0 | 53.68 | 47.93 | 34.2 | 35.01 | 9.19 |
| Payable days | 0 | 0 | 67.93 | 132.29 | 28.02 | 74.62 | 81.13 | 48.75 | 41.72 | 127.72 |
| PER(x) | 0 | 0 | 0 | 0 | 7.51 | 5.38 | 18.55 | 18.85 | 0 | 3.86 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0.59 | 0.98 | 3.38 | 4.56 | 1.3 | 0.31 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 3.07 | 1.2 | 0.99 | 0 | 0 |
| EV/Net Sales(x) | 0 | 0.45 | 8.83 | 0.46 | 0.13 | 0.35 | 1.39 | 3.42 | 0.93 | 0.36 |
| EV/Core EBITDA(x) | -0.42 | -0.4 | 72.45 | 4.12 | 2.9 | 2.22 | 9.32 | 9.81 | -1.89 | 1.92 |
| Net Sales Growth(%) | 0 | 0 | 3300 | 1872.31 | 592.64 | -30.82 | 13.43 | 65.83 | -39.98 | -29.29 |
| EBIT Growth(%) | -4131.82 | 47.26 | 471.54 | 1304.33 | 127.26 | 175.64 | 18.78 | 306.96 | -215.7 | 112.73 |
| PAT Growth(%) | 0 | 32.18 | 298 | 1124.48 | 131.8 | 169.92 | 26.3 | 297.73 | -283.36 | 111.06 |
| EPS Growth(%) | 0 | 32.18 | 100.64 | 631.24 | 101.59 | 169.92 | 26.3 | 199.06 | -283.36 | 111.06 |
| Debt/Equity(x) | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0 | 0.03 | 0.04 | 0.03 |
| Current Ratio(x) | 0.01 | 0.11 | 12.86 | 2.31 | 1.88 | 1.68 | 2.33 | 2.75 | 1.75 | 1.6 |
| Quick Ratio(x) | 0.01 | 0.11 | 12.19 | 2.31 | 1.88 | 1.05 | 1.64 | 2.26 | 1.71 | 1.54 |
| Interest Cover(x) | -3778.41 | -22.04 | 743.02 | 96.19 | 23.44 | 32.07 | 121.65 | 24.52 | -121.91 | 25.05 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0.02 | 0.01 | 0 | 0.01 | 0.03 | 0.09 |
| # | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 39.07 | 39.07 | 39.07 | 39.07 | 39.07 | 39.09 | 39.09 | 39.09 | 39.09 | 39.09 |
| FII | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0.03 | 0 | 0 | 0 | 0 |
| Public | 60.91 | 60.93 | 60.93 | 60.93 | 60.93 | 60.88 | 60.91 | 60.91 | 60.91 | 60.91 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -28% | -10% | -11% | — |
| Operating Profit CAGR | — | 0% | +20% | — |
| PAT CAGR | — | -13% | +15% | — |
| Share Price CAGR | 0% | -32% | -19% | -18% |
| ROE Average | +8% | -4% | +6% | +5% |
| ROCE Average | +10% | +4% | +15% | +11% |
| # | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 39.07 | 39.07 | 39.07 | 39.07 | 39.07 | 39.09 | 39.09 | 39.09 | 39.09 | 39.09 |
| FII | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0.03 | 0 | 0 | 0 | 0 |
| Public | 60.93 | 60.93 | 60.93 | 60.93 | 60.93 | 60.91 | 60.91 | 60.91 | 60.91 | 60.91 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.